Lopez-Goerne Tessy, Arellano Alfonso, Padilla-Godinez Francisco J, Magana Carlos, Gonzalez-Bondani Antonela, Valiente Rafael
Department of Health Care, Nanotechnology and Nanomedicine Laboratory, Metropolitan Autonomous University, Xochimilco, Mexico City, 04960, Mexico.
Department of Neurology and Neurosurgery, National Institute of Neurology and Neurosurgery, Mexico City, 14269, Mexico.
Curr Cancer Drug Targets. 2025;25(3):270-280. doi: 10.2174/0115680096289012240311023133.
BACKGROUND: Glioblastoma multiforme (GBM), the most prevalent form of central nervous system (CNS) cancer, stands as a highly aggressive glioma deemed virtually incurable according to the World Health Organization (WHO) standards, with survival rates typically falling between 6 to 18 months. Despite concerted efforts, advancements in survival rates have been elusive. Recent cutting-edge research has unveiled bionanocatalysts with 1% Pt, demonstrating unparalleled selectivity in cleaving C-C, C-N, and C-O bonds within DNA in malignant cells. The application of these nanoparticles has yielded promising outcomes. OBJECTIVE: The objective of this study is to employ bionanocatalysts for the treatment of Glioblastoma Multiforme (GBM) in a patient, followed by the evaluation of obtained tissues through electronic microscopy. METHODS: Bionanocatalysts were synthesized using established protocols. These catalysts were then surgically implanted into the GBM tissue through stereotaxic procedures. Subsequently, tissue samples were extracted from the patient and meticulously examined using Scanning Electron Microscopy (SEM). RESULTS AND DISCUSSION: Detailed examination of biopsies via SEM unveiled a complex network of small capillaries branching from a central vessel, accompanied by a significant presence of solid carbonate formations. Remarkably, the patient subjected to this innovative approach exhibited a three-year extension in survival, highlighting the potential efficacy of bionanocatalysts in combating GBM and its metastases. CONCLUSION: Bionanocatalysts demonstrate promise as a viable treatment option for severe cases of GBM. Additionally, the identification of solid calcium carbonate formations may serve as a diagnostic marker not only for GBM but also for other CNS pathologies.
背景:多形性胶质母细胞瘤(GBM)是中枢神经系统(CNS)癌症中最常见的形式,是一种极具侵袭性的胶质瘤,根据世界卫生组织(WHO)的标准,几乎被认为无法治愈,生存率通常在6至18个月之间。尽管人们齐心协力,但生存率的提高却难以实现。最近的前沿研究发现了含1%铂的生物纳米催化剂,其在切割恶性细胞DNA中的碳 - 碳、碳 - 氮和碳 - 氧键方面表现出无与伦比的选择性。这些纳米颗粒的应用已产生了有前景的结果。 目的:本研究的目的是使用生物纳米催化剂治疗一名多形性胶质母细胞瘤(GBM)患者,然后通过电子显微镜评估所获得的组织。 方法:使用既定方案合成生物纳米催化剂。然后通过立体定向手术将这些催化剂植入GBM组织中。随后,从患者身上提取组织样本,并使用扫描电子显微镜(SEM)进行细致检查。 结果与讨论:通过SEM对活检组织进行详细检查发现,从中央血管分支出来的小毛细血管形成了一个复杂的网络,同时还存在大量的固体碳酸盐形成物。值得注意的是,接受这种创新方法治疗的患者生存期延长了三年,突出了生物纳米催化剂在对抗GBM及其转移方面的潜在疗效。 结论:生物纳米催化剂有望成为GBM严重病例的一种可行治疗选择。此外,固体碳酸钙形成物的识别不仅可以作为GBM的诊断标志物,也可用于其他中枢神经系统疾病。
Curr Cancer Drug Targets. 2025
J Colloid Interface Sci. 2015-7-15
Nanomaterials (Basel). 2023-5-4
Nanomaterials (Basel). 2023-5-4
Nanomaterials (Basel). 2023-3-6
Nanomedicine (Lond). 2022-7
Endocr Relat Cancer. 2022-10-7
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023-1
Int J Low Extrem Wounds. 2022-8-9
Cancers (Basel). 2022-5-13
IEEE Trans Nanobioscience. 2022-4